Fusion AAV Capsid for Targeted Retinal and Cochlear Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adeno-associated virus (AAV) vectors for gene therapy in auditory and ophthalmic systems suffer from poor tissue specificity and low infection efficiency, leading to non-specific infections that can adversely affect disease therapy.
Innovation Solution
A fusion adeno-associated virus capsid protein composed of peptide fragments from AAV1, AAV2, AAV6, and AAV7, engineered to specifically target and infect cochlear supporting cells, hair cells in the cochlea, and the retinal RPE layer, enhancing infection efficiency and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional AAV vectors are used for gene therapy, then gene delivery can be achieved, but tissue specificity is poor and infection efficiency is low
Solution Approach 1:
The patent merges peptide fragments from multiple AAV serotypes (AAV1, AAV2, AAV6, AAV7) to create a fusion capsid protein. This combination allows the virus to inherit beneficial properties from each parent serotype, achieving both high tissue specificity for cochlear and retinal cells and high infection efficiency, thereby resolving the contradiction between reliability and productivity.
Solution Approach 2:
The fusion AAV capsid protein is a composite structure composed of peptide fragments from different AAV serotypes. This composite design enables the virus to exhibit enhanced tissue tropism for specific target cells (cochlear supporting cells, hair cells, retinal RPE cells) while maintaining high infection efficiency, simultaneously improving both reliability and productivity.
2Adaptability or versatility
If AAV vectors infect multiple cell types, then broad coverage is achieved, but non-specific infection reduces therapy effectiveness
Solution Approach 1:
The fusion AAV capsid protein exhibits local quality by demonstrating preferential affinity for specific cell types (cochlear supporting cells, hair cells, retinal RPE cells) through its engineered peptide composition. This targeted approach ensures broad coverage within the intended tissue while avoiding non-specific infection of unrelated cell types, thereby maintaining high therapy effectiveness.
3Reliability
If engineered AAV capsids are developed to evade neutralizing antibodies, then immune evasion is improved, but vector complexity increases
Solution Approach 1:
The patent combines peptide fragments from multiple AAV serotypes that have different immunogenic profiles. This merging strategy allows the engineered capsid to evade preexisting neutralizing antibodies by presenting a novel epitope structure that the immune system has not encountered, while the modular nature of the fusion protein keeps the design relatively simple and manageable.
Data Source
AI summary
The present invention relates to the field of biological medicines. Disclosed are a fusion adeno-associated virus and a use thereof in otological disease and ophthalmic diseases. The fusion adeno-associated virus comprises a fusion peptide fragment formed by fusion of peptide fragments of serotypes AAV1, AAV2, AAV6 and AAV7, or a variant thereof, and can efficiently infect an RPE layer for the treatment of ophthalmic diseases. The fusion adeno-associated virus has a wide application prospect in the treatment of ophthalmic diseases as a safe vector.